http://www.gilead.com/news/press-releases/2014/6/gilead-announces-phase-3-data-showing-that-the-fixeddose-combination-of-ledipasvirsofosbuvir-achieved-100-percent-sustained-virologic-response-svr12-among-patients-with-chronic-hepatitis-c-in-japan

您访问的网址可能存在安全风险，我们建议您停止继续浏览该网址，以防财产损失